At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 65 enrolled
Drug / intervention
Intravitreal Aflibercept Injection (IAI)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study in Patients With Chorioretinal Vascular Disease to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe
In Brief
A Phase 4 clinical trial evaluating Intravitreal Aflibercept Injection (IAI) for Chorioretinal Vascular Disease. Completed, enrolled 65 participants across 2 sites.
Detailed Summary
The primary objective of the study is to determine if the pre-filled syringe (PFS) supports successful preparation and accurate administration of an aflibercept injection. The secondary objective of the study is to assess ocular safety in the study eye.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChorioretinal Vascular Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartDec 2018
Primary CompletionAug 2020
TodayJul 2026
First PostedDec 7, 2018
Enrollment StartDec 19, 2018
Primary CompletionAug 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.6 years ago
Interventions
Intravitreal Aflibercept Injection (IAI)drug
IAI prepared and administered with a pre-filled syringe (PFS)